Recent submissions
Now showing items 81-100 of 4607
-
Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer
(Springer Science and Business Media LLC, 2024-01-29)<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Pre-clinical studies suggest AZD1775, a WEE1 kinase inhibitor, potentiates the activity of various ... -
Vitamin B5 supports MYC oncogenic metabolism and tumor progression in breast cancer.
(NATURE PORTFOLIO, 2023-11-01)Tumors are intrinsically heterogeneous and it is well established that this directs their evolution, hinders their classification and frustrates therapy1-3. Consequently, spatially resolved omics-level analyses are gaining ... -
Translational Aspects of Epithelioid Sarcoma: Current Consensus.
(AMER ASSOC CANCER RESEARCH, 2024-03-15)Epithelioid sarcoma (EpS) is an ultra-rare malignant soft-tissue cancer mostly affecting adolescents and young adults. EpS often exhibits an unfavorable clinical course with fatal outcome in ∼50% of cases despite aggressive ... -
Phosphatase specificity principles uncovered by MRBLE:Dephos and global substrate identification.
(SPRINGERNATURE, 2023-12-06)Phosphoprotein phosphatases (PPPs) regulate major signaling pathways, but the determinants of phosphatase specificity are poorly understood. This is because methods to investigate this at scale are lacking. Here, we develop ... -
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.
(AMER ASSOC CANCER RESEARCH, 2024-02-16)PURPOSE: Giredestrant is an investigational next-generation, oral, selective estrogen receptor antagonist and degrader for the treatment of estrogen receptor-positive (ER+) breast cancer. We present the primary analysis ... -
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
(ELSEVIER, 2023-12-01)BACKGROUND: In the phase 3 KEYNOTE-040 study, pembrolizumab prolonged OS versus chemotherapy in previously treated recurrent or metastatic (R/M) HNSCC. We present a post hoc subgroup analysis by disease recurrence pattern: ... -
Impact of germline DNA repair gene variants on prognosis and treatment of men with advanced prostate cancer.
(NATURE PORTFOLIO, 2023-11-06)The clinical importance of germline variants in DNA repair genes (DRGs) is becoming increasingly recognized, but their impact on advanced prostate cancer prognosis remains unclear. A cohort of 221 newly diagnosed metastatic ... -
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
(BMC, 2023-11-03)BACKGROUND: Ibrutinib, a first-in-class inhibitor of Bruton's tyrosine kinase, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. Based on encouraging preclinical data, ... -
EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy - Molecular radiotherapy.
(ELSEVIER SCI LTD, 2023-12-01)The European Council Directive 2013/59/Euratom (BSS Directive) includes optimisation of treatment with radiotherapeutic procedures based on patient dosimetry and verification of the absorbed doses delivered. The present ... -
Deep Learning Framework with Multi-Head Dilated Encoders for Enhanced Segmentation of Cervical Cancer on Multiparametric Magnetic Resonance Imaging.
(MDPI, 2023-11-03)T2-weighted magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) are essential components of cervical cancer diagnosis. However, combining these channels for the training of deep learning models is challenging ... -
Boosting and broadening recruitment to UK cancer trials: towards a blueprint for action
(BMJ, 2023-11-01)<jats:p>Recruitment and retention in cancer trials are long-standing issues, exacerbated by the COVID-19 pandemic. The UK National Institute of Health Research and leading clinicians have emphasised the urgency to achieve ... -
A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysis.
(ELSEVIER SCIENCE INC, 2023-11-01)BACKGROUND: Retroperitoneal sarcomas are tumours with a poor prognosis. Upfront characterisation of the tumour is difficult, and under-grading is common. Radiomics has the potential to non-invasively characterise the ... -
Relative fat fraction of malignant bone lesions from breast cancer, prostate cancer and myeloma are significantly lower than normal bone marrow and shows excellent interobserver agreement.
(BRITISH INST RADIOLOGY, 2023-11-01)OBJECTIVES: To compare relative fat fraction (rFF) of active bone lesions from breast, prostate and myeloma malignancies and normal bone marrow; to assess its inter-reader agreement. METHODS: Patients with breast (n = 26), ... -
Discarded livers tested by normothermic machine perfusion in the VITTAL trial: Secondary end points and 5-year outcomes.
(LIPPINCOTT WILLIAMS & WILKINS, 2024-01-01)Normothermic machine perfusion (NMP) enables pretransplant assessment of high-risk donor livers. The VITTAL trial demonstrated that 71% of the currently discarded organs could be transplanted with 100% 90-day patient and ... -
Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects.
(American Society of Clinical Oncology (ASCO), 2024-01-01)PURPOSE: The way late-onset toxicities are managed can affect trial outcomes and participant safety. Specifically, participants often might not have completed their entire follow-up period to observe any toxicities before ... -
Respiratory motion modelling for MR-guided lung cancer radiotherapy: model development and geometric accuracy evaluation.
(IOP Publishing Ltd, 2024-02-19)Objective.Respiratory motion of lung tumours and adjacent structures is challenging for radiotherapy. Online MR-imaging cannot currently provide real-time volumetric information of the moving patient anatomy, therefore ... -
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research.
(AMER ASSOC CANCER RESEARCH, 2024-03-15)After decades of research, improving the efficacy of adjuvant endocrine therapy (ET) for early-stage breast cancer becomes increasingly difficult. Beyond technological breakthroughs and the availability of new classes of ... -
The response of the Eukaryotic replisome to DNA quadruplex structures
(Institute of Cancer Research (University Of London), 2024-01-18)Sequences that can form DNA secondary structures, such as G-quadruplexes (G4s) and intercalated-Motifs (iMs), are abundant in the human genome and play a range of physiological roles. However, they can pose a challenge to ... -
Improving tumour target coverage in spine stereotactic radiotherapy
(Institute of Cancer Research (University Of London), 2024-01-16)Spine stereotactic body radiotherapy (SBRT) has high rates of local control. Local control failure rates are higher in cases with epidural disease and radioresistant histologies. A limiting factor is the proximity of the ...